Author/Authors :
Givi, Mahshid Heart Failure Research Center - Cardiovascular Research Institute - Isfahan University of Medical Sciences, Isfahan, Iran , Shafie, Davood Isfahan Cardiovascular Research Center - Cardiovascular Research Institute - Isfahan University of Medical Sciences, Isfahan, Iran , Garakyaraghi, Mohammad Heart Failure Research Center - Cardiovascular Research Institute - Isfahan University of Medical Sciences, Isfahan, Iran , Yadegarfar, Ghasem Heart Failure Research Center - Cardiovascular Research Institute - Isfahan University of Medical Sciences, Isfahan, Iran , Roohafza, Hamid Reza Isfahan Cardiovascular Research Center - Cardiovascular Research Institute - Isfahan University of Medical Sciences, Isfahan, Iran , Ahmadi, Abdollah Isfahan Cardiovascular Research Center - Cardiovascular Research Institute - Isfahan University of Medical Sciences, Isfahan, Iran , Nouri, Fatemeh Isfahan Cardiovascular Research Center - Cardiovascular Research Institute - Isfahan University of Medical Sciences, Isfahan, Iran , Sarrafzadegan, Nizal Isfahan Cardiovascular Research Center - Cardiovascular Research Institute - Isfahan University of Medical Sciences, Isfahan, Iran
Abstract :
Background: The Persian Registry of Cardiovascular disease/Heart Failure (PROVE/HF)
aimed to studied the demographic, clinical, and diagnostic characteristics and treatment of
patients hospitalized for heart failure (HF) and to follow them for short- and long-term outcomes.
Its pilot phase started in 2015 in Isfahan aiming to evaluate its feasibility to be scaled
up at the national level in later stages. This article describes the method and preliminary results
of the first year registry. Materials and Methods: Information of hospitalized patients
with preserved and low ejection fraction, were gathered. Patients were followed for 1, 6, and 12
months. During follow-up, information of the patients’ current status, medications used during
hospitalization, and in case of death, the cause and place were assessed. Result: PROVE/
HF enrolled 787 patients in the first year. The mean age of patients was 70.74 ±12.01 years,
and 60.7% of them were men. The most frequent risk factors for the development of HF in
the recruited patients was ischemic heart disease (77.9%), and hypertension (63.7%), respectively.
The re-admission rate for patients with HF was at least once in 16% and continued
until the fifth to ninth re-admission over a one-year period. Among 787 registered patients,
30.9% died in the first year of follow-up, and the in-hospital mortality was 6.2%. The mean
hospitalization period was 4.88 days, and 64.2% were hospitalized for >3 days. Conclusion:
The annual rate of re-admission and mortality was high, and the use of medication was less
than the recommended one inaccordance with the guidelines for the treatment of heart failure.
Keywords :
Heart Failure , Registries , Disease Management , Iran